围手术期或仅辅助吉西他滨联合白蛋白结合型紫杉醇治疗可切除胰腺癌(NEONAX)——AIO胰腺癌组的一项随机II期试验
NEONAX是一项前瞻性随机II期试验,将127例可切除胰腺导管腺癌患者随机分为围手术期组(术前2周期+术后4周期,A组)或辅助组(6周期,B组),采用吉西他滨联合白蛋白结合型紫杉醇方案。主要终点18个月无病生存率在两组均未达到预设的55%[A组33.3%(95%CI 18.5%-48.1%),B组41.4%(95%CI 20.7%-62.0%)]。次要终点中位总生存期A组25.5个月(95%CI 19.7-29.7),B组16.7个月(95%CI 11.6-22.2)。
要点
- 18个月无病生存率未达到预设55%:A组33.3%,B组41.4%,数值上 favoring 直接手术组B
- 中位总生存期A组25.5个月 vs B组16.7个月,数值上 favoring 新辅助组A
- A组90%完成术前化疗,B组42%开始辅助化疗;R0切除率A组88% vs B组67%
核心结论
- 主要终点18个月无病生存率在两组均未达到预设的55%,数值上 favoring 直接手术组B。
- 次要终点中位总生存期(ITT人群)数值上 favoring 新辅助组A[25.5个月(95%CI 19.7-29.7)vs B组16.7个月(95%CI 11.6-22.2)]。
- 围手术期/新辅助治疗是可切除胰腺导管腺癌患者的一种新选择,但最佳治疗方案尚未确定。
研究设计与样本
- NEONAX是一项前瞻性随机II期试验,包含两个独立实验组。
- 德国22个中心共127例可切除胰腺导管腺癌患者按1:1随机分组。
- A组为围手术期治疗(术前2周期+术后4周期),B组为辅助治疗(6周期),方案均为吉西他滨(1000 mg/m2)联合白蛋白结合型紫杉醇(125 mg/m2),28天周期第1、8、15天给药。
- 主要终点为改良意向治疗(mITT)人群[开始新辅助化疗(A组)或辅助化疗(B组)的R0/R1切除患者]的18个月无病生存率。
主要发现
- 18个月无病生存率:A组33.3%(95%CI 18.5%-48.1%),B组41.4%(95%CI 20.7%-62.0%),均未达到预设的55%。
- A组90%患者完成新辅助治疗,B组42%患者开始辅助化疗。
- R0切除率A组88%,B组67%。
- 中位总生存期(ITT人群):A组25.5个月(95%CI 19.7-29.7),B组16.7个月(95%CI 11.6-22.2)。
- 中位无病生存期(ITT):A组11.5个月(95%CI 8.8-14.5),B组5.9个月(95%CI 3.6-11.5)。
关键数值与推荐
- 可切除胰腺导管腺癌依据美国国家综合癌症网络(NCCN)标准判定。
- 吉西他滨剂量1000 mg/m2,白蛋白结合型紫杉醇剂量125 mg/m2,28天周期第1、8、15天给药。
- A组术前2周期、术后4周期;B组6周期。
临床怎么用
- 作者认为围手术期/新辅助治疗是可切除胰腺导管腺癌患者的一种新选择,但最佳治疗方案尚未确定。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on perioperative chemotherapy in resectable pancreatic ductal adenocarcinoma (rPDAC) are limited. NEONAX examined perioperative or adjuvant chemotherapy with gemcitabine plus nab-paclitaxel in rPDAC (National Comprehensive Cancer Network criteria). PATIENTS AND METHODS: NEONAX is a prospective, randomized phase II trial with two independent experimental arms. One hundred twenty-seven rPDAC patients in 22 German centers were randomized 1 : 1 to perioperative (two pre-operative and four post-operative cycles, arm A) or adjuvant (six cycles, arm B) gemcitabine (1000 mg/m2) and nab-paclitaxel (125 mg/m2) on days 1, 8 and 15 of a 28-day cycle. RESULTS: The primary endpoint was disease-free survival (DFS) at 18 months in the modified intention-to-treat (ITT) population [R0/R1-resected patients who started neoadjuvant chemotherapy (CTX) (A) or adjuvant CTX (B)]. The pre-defined DFS rate of 55% at 18 months was not reached in both arms [A: 33.3% (95% confidence interval [CI] 18.5% to 48.1%), B: 41.4% (95% CI 20.7% to 62.0%)]. Ninety percent of patients in arm A completed neoadjuvant treatment, and 42% of patients in arm B started adjuvant chemotherapy. R0 resection rate was 88% (arm A) and 67% (arm B), respectively. Median overall survival (mOS) (ITT population) as a secondary endpoint was 25.5 months (95% CI 19.7-29.7 months) in arm A and 16.7 months (95% CI 11.6-22.2 months) in the upfront surgery arm. This difference corresponds to a median DFS (mDFS) (ITT) of 11.5 months (95% CI 8.8-14.5 months) in arm A and 5.9 months (95% CI 3.6-11.5 months) in arm B. Treatment was safe and well tolerable in both arms. CONCLUSIONS: The primary endpoint, DFS rate of 55% at 18 months (mITT population), was not reached in either arm of the trial and numerically favored the upfront surgery arm B. mOS (ITT population), a secondary endpoint, numerically favored the neoadjuvant arm A [25.5 months (95% CI 19.7-29.7months); arm B 16.7 months (95% CI 11.6-22.2 months)]. There was a difference in chemotherapy exposure with 90% of patients in arm A completing pre-operative chemotherapy and 58% of patients starting adjuvant chemotherapy in arm B. Neoadjuvant/perioperative treatment is a novel option for patients with resectable PDAC. However, the optimal treatment regimen has yet to be defined. The trial is registered with ClinicalTrials.gov (NCT02047513) and the European Clinical Trials Database (EudraCT 2013-005559-34).
引用
- Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2022. PMID: 36209981. doi:10.1016/j.annonc.2022.09.161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。